Monday, May 20, 2013 Last update: 10:04 AM
Company Tech News as it Breaks
CryoLife, Inc.
News articles for CryoLife, Inc.:
Tuesday, April 30, 2013
- CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 MillionATLANTA, April 30, 2013 /PRNewswire/ -- First Quarter and Recent Highlights: -- Total revenues grew 10 percent year-over-year to a record $35.5 million -- Product revenues grew 20 percent year-over-year to $19.8 million -- Received 510(k) clearance for next ... read more
Tuesday, April 9, 2013
- CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial ResultsATLANTA, April 9, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 first quarter financial results will be released on Tuesday, April 30, 2013. On that day, the Company will ... read more
Monday, April 8, 2013
- CryoLife To Host Central Venous Pathology SummitATLANTA, April 8, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will host a Central Venous Pathology (CVP) Summit on April 18-19, 2013 at CryoLife's training facility at its ... read more
Thursday, April 4, 2013
- CryoLife Receives FDA Clearance For Next Generation HeRO DeviceATLANTA, April 4, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) ... read more
Thursday, February 14, 2013
- CryoLife Expands Stock Repurchase ProgramATLANTA, Feb. 14, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that its Board of Directors authorized the Company's purchase of $15 million of its common stock through October 31, 2014. ... read moreCryoLife 2012 Annual Revenues Grew to a Record $131.7 MillionATLANTA, Feb. 14, 2013 /PRNewswire/ -- Full Year Highlights: -- Total revenues grew 10% year-over-year to a record $131.7 million -- Product revenues grew 14% year-over-year to $67.5 million -- Tissue processing revenues grew 6% year-over-year to $63.6 million ... read more
Wednesday, February 13, 2013
- CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013ATLANTA, Feb. 13, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2013 of $0.025 per share of ... read more
Thursday, January 31, 2013
- CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial ResultsATLANTA, Jan. 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2012 fourth quarter and year end financial results will be released on Thursday, February 14, 2013. On that day, ... read more
Wednesday, December 5, 2012
- CryoLife Receives Expanded Indication for BioFoam in EuropeATLANTA, Dec. 5, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received regulatory approval in Europe to market its BioFoam® Surgical Matrix as an adjunct to hemostasis in cardiovascular ... read more